Supernus Pharmaceuticals Inc Quick Ratio (SUPN) starting from the second quarter 2026 to second quarter 2025, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Supernus Pharmaceuticals inc   (NASDAQ: SUPN)

Supernus Pharmaceuticals Inc 's Quick Ratio

SUPN's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


In the wake of the increase in Current Liabilities in the second quarter 2026, Quick Ratio fell to 0.52 below Supernus Pharmaceuticals Inc average.

Within Major Pharmaceutical Preparations industry 392 other companies have achieved higher Quick Ratio than Supernus Pharmaceuticals Inc in second quarter 2026. While Quick Ratio total ranking has improved so far during the Q2 2026 to 2001, from total ranking in the first quarter 2026 at 2809.

Explain Quick Ratio?
How much Cash & cash equivalents SUPN´s has?
What are SUPN´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

SUPN Quick Ratio (Jun 30 2026)
Q2		 (Mar 31 2026)
Q1		 (Dec 31 2025)
Q4		 (Sep 30 2025)
Q3		 (Jun 30 2025)
Q2
Y / Y Current Liabilities Change 229.44 % 65 % 36.7 % 19.44 % -21.04 %
Y / Y Cash & cash equivalent Change 24.49 % 59.58 % 85.27 % 377.92 % 177.81 %
Quick Ratio MRQ 0.52 1 0.73 1.04 1.37
SUPN's Total Ranking # 2001 # 2809 # 2233 # 1983 # 2316
Seq. Current Liabilities Change 88.58 % 4.03 % 21.14 % 38.62 % -5.55 %
Seq. Cash & cash equivalent Change -2.56 % 43.93 % -15.14 % 4.6 % 24.91 %



Quick Ratio second quarter 2026 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 393
Healthcare Sector # 739
Overall Market # 2589


Quick Ratio Statistics
High Average Low
8.86 2.24 0.08
(Mar 31 2020)   (Mar 31 2023)




Financial Statements
Supernus Pharmaceuticals Inc 's Current Liabilities $ 347 Millions Visit SUPN's Balance sheet
Supernus Pharmaceuticals Inc 's Cash & cash equivalent $ 180 Millions Visit SUPN's Balance sheet
Source of SUPN's Sales Visit SUPN's Sales by Geography


Cumulative Supernus Pharmaceuticals Inc 's Quick Ratio

SUPN's Quick Ratio for the trailling 12 Months

SUPN Quick Ratio

 (Jun 30 2026)
12 Months		 (Mar 31 2026)
12 Months		 (Dec 31 2025)
12 Months		 (Sep 30 2025)
12 Months		 (Jun 30 2025)
12 Months
Y / Y Current Liabilities TTM Growth 82.27 % 23.3 % 1.42 % -28.94 % -32.63 %
Y / Y Cash & cash equivalent TTM Growth 78.35 % 126.59 % 149.6 % 115.87 % 26.31 %
Quick Ratio TTM 0.75 0.99 1 0.98 0.77
Total Ranking TTM # 2086 # 2474 # 1937 # 2185 # 2494
Seq. Current Liabilities TTM Growth 39.47 % 13.43 % 9.65 % 5.07 % -5.65 %
Seq. Cash & cash equivalent TTM Growth 5.81 % 12.77 % 12.28 % 33.11 % 34.44 %

Quick ratio ranking by company, industry and sector >> Back to SUPN Financial Strength Comparisons >> Go to Compare SUPN Quick Ratio to its Competitors

On the trailing twelve months basis Due to jump in Current Liabilities in the Q2 2026 to $347.38 millions, cumulative Quick Ratio decreased to 0.75 below the Supernus Pharmaceuticals Inc average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 439 other companies have achieved higher Quick Ratio than Supernus Pharmaceuticals Inc . While Quick Ratio overall ranking has improved so far to 0, from total ranking during the twelve months ending first quarter 2026 at 2986.

Explain Quick Ratio?
How much Cash & cash equivalents SUPN´s has?
What are SUPN´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 440
Healthcare Sector # 903
Within the Market # 2001


trailing twelve months Quick Ratio Statistics
High Average Low
1.59 0.76 0.12
(Mar 31 2018)  




Companies with similar Quick Ratio in the quarter ending Jun 30 2026, within Major Pharmaceutical Preparations Industry Quick RatioJun 30 2026 MRQ Cash & cash equivalentJun 30 2026 MRQ Current Liabilities
Kyntra Bio Inc   1.41 $ 50.644  Millions$ 36.040  Millions
Medicus Pharma Ltd   1.40 $ 15.174  Millions$ 10.841  Millions
Aurinia Pharmaceuticals Inc   1.39 $ 179.732  Millions$ 129.084  Millions
Omeros Corporation  1.39 $ 131.953  Millions$ 94.963  Millions
Avenue Therapeutics Inc   1.38 $ 1.942  Millions$ 1.407  Millions
Royalty Pharma Plc  1.33 $ 836.986  Millions$ 630.928  Millions
Cormedix Inc   1.31 $ 256.692  Millions$ 196.535  Millions
Transcode Therapeutics Inc   1.30 $ 8.383  Millions$ 6.430  Millions
Elite Pharmaceuticals Inc   1.28 $ 39.032  Millions$ 30.442  Millions
Ani Pharmaceuticals Inc  1.27 $ 360.212  Millions$ 283.655  Millions
Pmgc Holdings Inc   1.25 $ 19.126  Millions$ 15.329  Millions
Petros Pharmaceuticals inc   1.23 $ 3.489  Millions$ 2.845  Millions
Nature s Sunshine Products inc   1.20 $ 82.503  Millions$ 68.745  Millions
Phathom Pharmaceuticals Inc   1.19 $ 182.478  Millions$ 153.777  Millions
Compass Pathways Plc  1.18 $ 433.720  Millions$ 367.285  Millions
Geovax Labs Inc   1.17 $ 3.163  Millions$ 2.712  Millions
Actuate Therapeutics Inc   1.16 $ 4.426  Millions$ 3.805  Millions
Apimeds Pharmaceuticals US, Inc.  1.16 $ 8.278  Millions$ 7.166  Millions
Emergent Biosolutions Inc   1.14 $ 139.700  Millions$ 122.800  Millions
Turn Therapeutics Inc   1.14 $ 9.958  Millions$ 8.764  Millions
Ionis Pharmaceuticals Inc   1.11 $ 350.065  Millions$ 315.638  Millions
Oramed Pharmaceuticals Inc  1.00 $ 16.091  Millions$ 16.044  Millions
Inmed Pharmaceuticals Inc  1.00 $ 2.240  Millions$ 2.235  Millions
Nkarta Inc   1.00 $ 24.958  Millions$ 24.924  Millions
Inovio Pharmaceuticals Inc   1.00 $ 36.700  Millions$ 36.678  Millions
Jazz Pharmaceuticals Plc  0.98 $ 2,199.800  Millions$ 2,239.400  Millions
Akebia Therapeutics Inc   0.97 $ 155.548  Millions$ 160.865  Millions
Syndax Pharmaceuticals Inc   0.95 $ 342.883  Millions$ 360.284  Millions
Nurix Therapeutics Inc   0.94 $ 67.840  Millions$ 72.020  Millions
Theriva Biologics inc   0.94 $ 11.337  Millions$ 12.111  Millions

Date modified: 2026-09-13T23:36:29+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.